Search hospitals > Wisconsin > Oconto Falls
Saint Vincent Hospital Cancer Center at Oconto Falls
Claim this profileOconto Falls, Wisconsin 54154
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Recurrence
Conducts research for Non-Small Cell Lung Cancer
285 reported clinical trials
4 medical researchers
Summary
Saint Vincent Hospital Cancer Center at Oconto Falls is a medical facility located in Oconto Falls, Wisconsin. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Non-Small Cell Lung Cancer and other specialties. Saint Vincent Hospital Cancer Center at Oconto Falls is involved with conducting 285 clinical trials across 420 conditions. There are 4 research doctors associated with this hospital, such as Matthew L. Ryan, Brian L. Burnette, Anthony J. Jaslowski, and Catherine A. Long.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Matthew L. RyanSaint Vincent Hospital Cancer Center Green Bay1 year of reported clinical research
Expert in Cancer
Studies Recurrence
45 reported clinical trials
103 drugs studied
Brian L. BurnetteSaint Vincent Hospital Cancer Center Green Bay4 years of reported clinical research
Expert in Cancer
Studies Breast Cancer
30 reported clinical trials
82 drugs studied
Anthony J. JaslowskiSaint Vincent Hospital Cancer Center Green Bay5 years of reported clinical research
Expert in Cancer
Studies Breast Cancer
23 reported clinical trials
42 drugs studied
Catherine A. LongSaint Vincent Hospital Cancer Center Green Bay4 years of reported clinical research
Studies Tumors
Studies Cancer
21 reported clinical trials
56 drugs studied
Clinical Trials running at Saint Vincent Hospital Cancer Center at Oconto Falls
Breast Cancer
Non-Small Cell Lung Cancer
Cancer
Lung Cancer
Diffuse Large B-Cell Lymphoma
Melanoma
Multiple Myeloma
Lymphoma
Pancreatic Cancer
Recurrence
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Saint Vincent Hospital Cancer Center at Oconto Falls?
Saint Vincent Hospital Cancer Center at Oconto Falls is a medical facility located in Oconto Falls, Wisconsin. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Non-Small Cell Lung Cancer and other specialties. Saint Vincent Hospital Cancer Center at Oconto Falls is involved with conducting 285 clinical trials across 420 conditions. There are 4 research doctors associated with this hospital, such as Matthew L. Ryan, Brian L. Burnette, Anthony J. Jaslowski, and Catherine A. Long.